Everolimus is a derivative of sirolimus (rapamycin), which is clinically used primarily to prevent rejection after kidney transplantation and heart transplantation. Its mechanism of action mainly includes immunosuppressive effects, anti-tumor effects, antiviral effects, and vascular protection. Everolimus is a new generation of macrolides developed by Novartis AG and first launched in Germany in March 2004.
Sample analysis:
Column: Kromasil 4.6*250mm C18 5μm
Flow rate: 1ml/min
Column temperature: 40 ° C
Detection wavelength: 275nm
Mobile phase: A-water; B-acetonitrile
The crude product was analyzed and the sample purity was 76.0%.
Sample preparation (small test):
Equipment: HP compact; Column: C18 column 10μm 20*250mm; sample loading: 50mg
Solvent: acetonitrile-water; wavelength: 275 nm, 250 nm; flow rate: 15 ml/min
Post-preparation analysis: The main peaks of the preparation were collected and combined, and the samples were analyzed according to the above standard method, the purity was up to 99.5%, and the room temperature was allowed to stand overnight, and then the purity was decreased, and the purity was decreased to 98.9%.
Sample preparation (zoom in):
Equipment: HP compact; Column: C18 column 10μm 20*250mm; sample loading: 450mg
Solvent: acetonitrile-water; wavelength: 275 nm, 250 nm; flow rate: 15 ml/min
Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshimedicals.com